Premium
Melatonin and 5‐fluorouracil co‐suppress colon cancer stem cells by regulating cellular prion protein‐Oct4 axis
Author(s) -
Lee Jun Hee,
Yun Chul Won,
Han YongSeok,
Kim SangMin,
Jeong Dongjun,
Kwon Hyog Young,
Kim Hyeongjoo,
Baek MooJun,
Lee Sang Hun
Publication year - 2018
Publication title -
journal of pineal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 131
eISSN - 1600-079X
pISSN - 0742-3098
DOI - 10.1111/jpi.12519
Subject(s) - melatonin , fluorouracil , colorectal cancer , prion protein , stem cell , biology , cancer research , cancer stem cell , cancer , microbiology and biotechnology , medicine , endocrinology , genetics , disease
Melatonin suppresses tumor development. However, the exact relationship between melatonin and cancer stem cells ( CSC s) is poorly understood. This study found that melatonin inhibits colon CSC s by regulating the Pr P C ‐Oct4 axis. In specimens from patients with colorectal cancer, the expressions of cellular prion protein (Pr P C ) and Oct4 were significantly correlated with metastasis and tumor stages. Co‐treatment with 5‐fluorouracil (5‐ FU ) and melatonin inhibited the stem cell markers Oct4, Nanog, Sox2, and ALDH 1A1 by downregulating Pr P C . In this way, tumor growth, proliferation, and tumor‐mediated angiogenesis were suppressed. In colorectal CSC s, PRNP overexpression protects Oct4 against inhibition by 5‐ FU and melatonin. In contrast, Nanog, Sox2, and ALDH 1A1 have no such protection. These results indicate that Pr P C directly regulates Oct4, whereas it indirectly regulates Nanog, Sox2, and ALDH 1A1. Taken together, our findings suggest that co‐treatment with anticancer drug and melatonin is a potential therapy for colorectal cancer. Furthermore, Pr P C maintains cancer stemness during tumor progression. Therefore, targeting the Pr P C ‐Oct4 axis may prove instrumental in colorectal cancer therapy.